Shijiazhuang Pharmaceutical And Unigene Laboratories To Jointly Produce Osteoporosis Drug
This article was originally published in PharmAsia News
Executive Summary
Shijiazhuang Pharmaceutical recently signed an agreement with U.S.-based Unigene Laboratories to co-invest $15 million in a firm to produce the anti-osteoporosis product Salmon Calcitonin. When in operation, the joint venture will produce 70 million Calcitonin injections and 4 million bottles of nasal spray, with an expected 708 million yuan in sales and $51.2 million in foreign exchange per year. In addition, an R&D platform for manufacturing biologics will be set up to develop and commercialize biotech drugs for an international market. (Click here for more)